Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-546 Safety and Tolerability in Japanese SLE Patients
NCT01559090Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Apr 2012; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01559090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01559090.